Pharmacokinetics and therapeutic drug monitoring of anticancer agents;Pharmacocinétique et adaptation de posologie des agents anticancéreux

Bulletin du Cancer

Volumn 95, Issue 10, 2008, Pages 903-909

  Marquet, Pierre ^a   Rousseau, Annick ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Adjustment strategies; Clinical trials; Therapeutic drug monitoring

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTARABINE; FLUOROURACIL; METHOTREXATE; TENIPOSIDE;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; HEAD AND NECK CANCER; HUMAN; LYMPHATIC LEUKEMIA; REVIEW;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG MONITORING; HUMANS;

EID: 56149083908     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0725     Document Type: Review

References (28)

1. Masson E, Zamboni WC. Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. Clin Pharmacokinet 1997 ; 32 : 324-43.
2. Bacci G, Ferrari S, Delepine N, Bertoni F, Picci P, Mercuri M, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity : study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 1998 ; 1 : 658-63.
3. Joel S, O'Byrne K, Penson R, Papamichael D, Higgins A, Robertshaw H, et al. A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer. Ann Oncol 1998 ; 9 : 1205-11.
4. Salas S, Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Tranchand B, et al. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma. Ther Drug Monit 2006 ; 28 : 532-9.
5. Rousseau A, Marquet P, Debord J, Sabot C, Lachâtre G. Adaptive control methods for the dose individualisation of anticancer agents. Clin Pharmacokinet 2000 ; 38 : 315-53.
6. de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH. Individualised cancer chemotherapy : strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation : a review. Clin Pharmacokinet 2005 ; 44 : 147-73.
7. Marquet P. «Suivi thérapeutique pharmacologique : justification et intérêt». In : Marquet P, ed. Suivi thérapeutique pharmacologique pour l'adaptation de posologie des médicaments. Paris : Elsevier, 2004.
8. Marquet P. Suivi thérapeutique pharmacologique : aspects analytiques, pharmacocinéciques et cliniques. Acta Clin Belg 1999(suppl. 1) : 2-12.
9. Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman WP, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 1986 ; 314 : 471-7.
10. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992 ; 10 : 520-8.
11. Milano G, Etienne MC, Renée N, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994 ; 12 : 1291-5.
12. Segura C, Afchain P, de Gramont A, André T, and Gercor (French Oncology Research Group). Adjuvant treatment of colorectal cancer. Bull Cancer 2006 ; 93(7) : 683-90.
13. Tournigand C, de Gramont A. Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer. Bull Cancer 2006 ; 93 : S11-S15.
14. Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol 2002 ; 16 : 253-62.
15. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for industry : population pharmacokinetics. www.fda.gov/cder/guidance/1852fnl.pdf (consulté le 30/11/2007).
16. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998 ; 338 : 499-505.
17. Fety R, Rolland F, Barberi-Heyob M, Hardouin A, Campion L, Conroy T, et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil : results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 1998 ; 4 : 2039-45.
18. Toffoli G, Corona G, Basso B, Boiocchi M. Pharmacokinetic optimisation of treatment with oral etoposide. Clin Pharmacokinet 2004 ; 43 : 441-66.
19. Montazeri A, Culine S, Laguerre B, Pinguet F, Lokiec F, Albin N, et al. Individual adaptive dosing of topotecan in ovarian cancer. Clin Cancer Res 2002 ; 8 : 394-9.
20. Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res 1985 ; 45 : 6502-6.
21. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage : prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989 ; 7 : 1748-56.
22. Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995 ; 87 : 573-80.
23. Cano JP, Bruno R, Lena N, Favre R, Iliadis A, Imbert AM. Dosage predictions in high-dose methotrexate infusions. Part 1 : Evaluation of the classic test-dose protocol. Cancer Drug Deliv 1985 ; 2 : 271-6.
24. Gamelin E, Boisdron-Celle M, Delva R, Regimbeau C, Cailleux PE, Alleaume C, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin : results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998 ; 16 : 1470-8.
25. Odoul F, Le Guellec C, Lamagnère JP, et al. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. Fundam Clin Pharmacol 1999 ; 13 : 595-604.
26. Marquet P. Clinical application of population pharmacokinetic methods developed for immunosuppressive drugs. Ther Drug Monit 2005 ; 27 : 727-32.
27. Rousseau A. «Les médicaments anticancéreux : généralités». In : Marquet Pierre, ed. Suivi thérapeutique pharmacologique pour l'adaptation de posologie des médicaments. Paris : Elsevier, 2004.
28. Ploylearmsaeng SA, Fuhr U, Jetter A. How may anticancer chemotherapy with fluorouracil be individualised ? Clin Pharmacokinet 2006 ; 45 : 567-92.